Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified candidate treatment targets and potential prognostic markers for high-grade glioma, an aggressive brain cancer, in children, adolescents, and young adults. Read more: https://www.mountsinai.org/about/newsroom/2026/study-identifies-candidate-treatment-targets-for-high-grade-glioma-in-children-and-young-adults

Childhood brain tumors that form working electrical connections with healthy neurons grow more slowly in animals treated with an anti-seizure drug, Stanford Medicine research showed. Read more: https://med.stanford.edu/news/all-news/2026/09/seizure-drug-gliomas.html

The study, published in Practical Radiation Oncology, is the first to examine the experience of giving three courses of radiation treatment to patients with diffuse intrinsic pontine glioma (DIPG) that has recurred. Read more: https://medicalxpress.com/news/2026-09-largest-courses-children-deadly-brain.html/

When researchers at Lund University investigated how the molecule UM171 works, a molecule used to make blood stem cells multiply, they made an unexpected connection. The results provide new insights into how one of the most common malignant brain tumors in children could be treated in the future. Read more: https://www.news-medical.net/news/20260827/Unexpected-discovery-points-to-a-possible-route-for-childhood-brain-tumor-treatments.aspx

Now, a new Phase 1 trial led by researchers at Children’s National Hospital showed that a new autologous multi-antigen T cell therapy can be delivered intravenously and reach the brain through the bloodstream to fight off brain tumors in children. Read more: https://www.drugdiscoverynews.com/new-autologous-t-cell-therapy-offers-hope-for-children-with-brain-tumors-17325

Researchers from Fox Chase Cancer Center have identified a widely used thyroid hormone that may significantly improve treatment outcomes for medulloblastoma, the most common malignant brain tumor in children. Read more: https://medicalxpress.com/news/2026-07-common-thyroid-hormone-brain-tumor.html

Researchers report encouraging early results from a first-in-human clinical trial led by Children's National Hospital using a new T-cell immunotherapy for children and young adults with some of the deadliest brain tumors, including diffuse intrinsic pontine glioma (DIPG) and relapsed central nervous system (CNS) tumors. Read more: https://medicalxpress.com/news/2026-06-tcell-therapy-tumor-proteins-early.html

Through advanced genetic sequencing, chemotherapy and the expertise of a large medical team, doctors were able to identify a treatment approach tailored to Hadley's unique tumor. With the help of precision medicine and months of treatment, Hadley began defying expectations. Read more: https://www.cbsnews.com/colorado/news/childhood-brain-stem-cancer-survivor-colorado-girl/

A Children’s Hospital Los Angeles study has shed new light on the molecular drivers of FOXR2-activated CNS neuroblastoma, an extremely rare pediatric brain tumor that can be difficult to diagnose without advanced testing. Read more: https://www.newswise.com/articles/children-s-hospital-los-angeles-researchers-uncover-genetic-clues-to-rare-childhood-brain-tumor

Physical functioning is significantly diminished by intensive management of childhood posterior fossa brain tumors (PFTs) and correlates with survivors’ neurologic treatment burdens, suggests research presented at the 51st Annual ONS Congress in San Antonio, Texas. Read more: https://www.oncologynurseadvisor.com/reports/brain-tumors-functional-challenges-long-term-pediatric-pft/